Chronic Obstructive Pulmonary Disease Market Growth 2024, Rising Trends, CAGR Status, Challenges, Future Opportunities and Forecast till 2033: SPER Market Research
Chronic Obstructive Pulmonary Disease (COPD) Market is projected to be worth USD 33.31 billion by 2033 and is anticipated to surge at a CAGR of 4.68%.
Chronic obstructive pulmonary disease (COPD), a degenerative lung disease, is characterized by persistent respiratory symptoms and airflow restriction. It encompasses conditions like emphysema and chronic bronchitis that are primarily caused by long-term exposure to harmful gases or particles, most commonly by smoking. Coughing, wheezing, and increased mucus production are all symptoms of the illness's inflammation and destruction to the lung tissue and airways, which makes breathing difficult. COPD significantly impairs quality of life since it often leads to fatigue and a reduction in physical activity.
According to SPER Market Research, ‘Global Chronic Obstructive Pulmonary Disease (COPD) Market Size- By Type, By Treatment Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to reach USD 33.31 billion by 2033 with a CAGR of 4.68%.
Drivers:
The National Center for Biotechnology Information's 2019 survey, which found 212.3 million cases globally, highlights the rising incidence of chronic obstructive pulmonary disease (COPD). 74.4 million disability-adjusted life years (DALYs) and 3.3 million deaths were caused by this disorder. Furthermore, according to the American Lung Association, 9.0 million persons (3.6% of those aged 18 and older) suffered from chronic bronchitis in 2018. In addition, 16.4 million persons (6.6%) reported having a diagnosis of COPD, which includes emphysema and chronic bronchitis. The market for treatments and interventions is expected to develop significantly in the near future due to the rising incidence of COPD.
Restraints:
There are several significant barriers to growth and expansion in the chronic obstructive pulmonary disease (COPD) market. The underdiagnosis and delayed diagnosis of COPD are serious issues since many patients wait until their condition has gotten worse before seeking treatment, which means they miss out on opportunities for early intervention. The complexity of managing COPD, which often requires a multidisciplinary approach and a range of treatment options, may also make it more difficult to provide effective patient care and adherence. The high costs and financial burden of maintaining chronic diseases, particularly in low-income areas, may prevent many patients from accessing new medicines.
Request a Free Sample Report: https://www.sperresearch.com/report-store/chronic-obstructive-pulmonary-disease-market.aspx?sample=1
The global market for chronic obstructive pulmonary disease (COPD) has been significantly impacted by the COVID-19 pandemic, presenting both potential and challenges. Because of their underlying respiratory disorders, those with COPD were more vulnerable during the pandemic, leading to an increase in hospitalizations and a focus on respiratory health. Prioritizing COVID-19 responses often caused healthcare systems to disrupt regular care and management of COPD, which impacted patients' access to medications and made their illnesses worse.
Asia Pacific is dominated the Global Chronic Obstructive Pulmonary Disease (COPD) Market due to the increasing adoption of advanced healthcare solutions. Major players in the market are Pfizer Inc, Merck & Co., Inc, Novartis AG, AstraZeneca, GlaxoSmithKline plc, Roche (F. Hoffmann-La Roche Ltd, Switzerland), Abbott.
Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation:
By Type: Based on the Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Chronic Bronchitis, Emphysema.
By Treatment Type: Based on the Treatment Type, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Bronchodilator monotherapy, short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), anti-cholinergic agents, anti-inflammatory drugs, oral and inhaled corticosteroids, anti-leukotrienes, surgery, lung volume reduction surgery (LVRS), lung transplant, bullectomy and others.
By End User: Based on the End User, Global Chronic Obstructive Pulmonary Disease (COPD) Market is segmented as; Hospitals, Homecare Settings, Clinics, Others
By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.
For More Information, refer to below link: –
Chronic Obstructive Pulmonary Disease Market Outlook
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
+1-347-460-2899
What's Your Reaction?
